Overall market sentiment has been high on Applied Therapeutics Inc (APLT) stock lately. APLT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Applied Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on APLT!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With APLT Stock Today?
Applied Therapeutics Inc (APLT) stock is trading at $2.74 as of 1:27 PM on Thursday, Sep 28, a rise of $0.10, or 3.79% from the previous closing price of $2.64. The stock has traded between $2.52 and $2.81 so far today. Volume today is less active than usual. So far 579,325 shares have traded compared to average volume of 1,125,357 shares.
More About Applied Therapeutics Inc
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
Click Here to get the full Stock Report for Applied Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
